The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Ontario, Canada.
Program in Genetics and Genome Biology (GGB), The Hospital for Sick Children, Toronto, Ontario, Canada.
Sci Rep. 2016 Jul 1;6:28663. doi: 10.1038/srep28663.
A challenge in clinical genomics is to predict whether copy number variation (CNV) affecting a gene or multiple genes will manifest as disease. Increasing recognition of gene dosage effects in neurodevelopmental disorders prompted us to develop a computational approach based on critical-exon (highly expressed in brain, highly conserved) examination for potential etiologic effects. Using a large CNV dataset, our updated analyses revealed significant (P < 1.64 × 10(-15)) enrichment of critical-exons within rare CNVs in cases compared to controls. Separately, we used a weighted gene co-expression network analysis (WGCNA) to construct an unbiased protein module from prenatal and adult tissues and found it significantly enriched for critical exons in prenatal (P < 1.15 × 10(-50), OR = 2.11) and adult (P < 6.03 × 10(-18), OR = 1.55) tissues. WGCNA yielded 1,206 proteins for which we prioritized the corresponding genes as likely to have a role in neurodevelopmental disorders. We compared the gene lists obtained from critical-exon and WGCNA analysis and found 438 candidate genes associated with CNVs annotated as pathogenic, or as variants of uncertain significance (VOUS), from among 10,619 developmental delay cases. We identified genes containing CNVs previously considered to be VOUS to be new candidate genes for neurodevelopmental disorders (GIT1, MVB12B and PPP1R9A) demonstrating the utility of this strategy to index the clinical effects of CNVs.
临床基因组学的一个挑战是预测影响一个或多个基因的拷贝数变异 (CNV) 是否会表现为疾病。神经发育障碍中基因剂量效应的不断认识促使我们开发了一种基于关键外显子(在大脑中高度表达,高度保守)检查的潜在病因效应的计算方法。使用大型 CNV 数据集,我们的更新分析显示,与对照组相比,病例中罕见 CNV 中的关键外显子显著富集(P < 1.64 × 10(-15))。另外,我们使用加权基因共表达网络分析 (WGCNA) 从产前和成人组织中构建了一个无偏的蛋白质模块,并发现它在产前组织中显著富集关键外显子(P < 1.15 × 10(-50),OR = 2.11)和成人组织(P < 6.03 × 10(-18),OR = 1.55)。WGCNA 产生了 1206 种蛋白质,我们将相应的基因优先作为神经发育障碍的候选基因。我们比较了从关键外显子和 WGCNA 分析中获得的基因列表,在 10619 例发育迟缓病例中发现了 438 个候选基因与 CNV 相关,这些基因被注释为致病性或意义未明的变异体 (VOUS)。我们确定了包含先前被认为是 VOUS 的 CNV 的基因是神经发育障碍的新候选基因(GIT1、MVB12B 和 PPP1R9A),证明了这种策略索引 CNV 临床效应的实用性。